Tests two red blood cell transfusion levels in adults with acute leukemia
Compares two hemoglobin levels for red cell transfusions in adults with leukemia.
Key facts
- Who runs it
- University of Washington
- Where
- Seattle, United StatesSee the site
- Trial code
- Registry title
- Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 15 Oct 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Activity Tracking
- Biospecimen Collection
- Cognitive Assessment
- Electronic Health Record Review
- Packed Red Blood Cell Transfusion
- Quality-of-Life Assessment
- Record updated
- 19 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high-grade myeloid neoplasm, acute myeloid leukemia or B-cell acute lymphoblastic lymphoma/leukemia who will have intensive chemotherapy or an allogeneic stem cell transplant.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- High-grade myeloid neoplasm (10% or more blasts in blood or bone marrow), acute myeloid leukemia (not acute promyelocytic leukemia), or B-cell acute lymphoblastic lymphoma/leukemia, by the 2022 WHO classification
- Earlier treatment
- Planned intensive chemotherapy ("7+3", hyper-CVAD, or a cytarabine-based regimen of 1,000mg/m^2 or more) or allogeneic stem cell transplant, expected to cause anemia needing red blood cell transfusion and platelets of 30,000/uL or lower for 5 days or more
Main reasons for not taking part
- Needs platelet transfusions at levels above 10,000/uL
- Needs blood thinners, anti-platelet or antifibrinolytic drugs that will not be held when platelets fall below 50,000/uL
- Bleeding of grade 2 or higher at the time of randomization
- Blood clot or heart attack in the 6 months before chemotherapy or transplant
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥ 18 years
- Diagnosis of "high-grade" myeloid neoplasm (≥ 10% blasts in blood or bone marrow) or acute myeloid leukemia (AML) (other than acute promyelocytic leukemia [APL]) or B-cell acute lymphoblastic lymphoma/leukemia (ALL) according to the 2022 WHO classification. Outside diagnostic material is acceptable to establish diagnosis
- Plan to undergo intensive chemotherapy induction or post-remission therapy for their diagnosis (defined as "7+3," hyper-cyclophosphamide, vincristine, doxorubicin, and dexamethasone [CVAD], or regimen with cytarabine backbone ≥ 1,000mg/m\^2), or allogeneic HSCT, expected to induce anemia requiring PRBC transfusion AND platelet counts of ≤ 30,000/uL for ≥ 5 days following the therapy (as determined by principal investigator)
- Plan to get all post-chemotherapy/post-HSCT care at the University of Washington (UW)/Fred Hutchinson Cancer Center (FHCC)
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Arterial or venous thrombotic event, including myocardial infarction within 6 months prior to initiation of the chemotherapy/HSCT
- Patients requiring renal replacement therapy at the time of randomization
- Patients with grade ≥ 2 bleeding (as determined by the WHO Bleeding Criteria) at the time of randomization
- Patients requiring a prophylactic platelet transfusion at thresholds > 10,000/uL
- Patients requiring systemic anticoagulation, anti-platelet agent, or antifibrinolytic therapy that will not be held once platelets reach a level of < 50,000/uL
- Patients who decline transfusion for personal or religious beliefs
- Pregnancy or lactation
Where in United States
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesContact: Anna Halpern, MDTaking people
About the trial
What the trial wants to find out
This clinical trial evaluates the effects of hemoglobin threshold-specific packed red blood cell (PRBC) transfusions on quality of life and functional outcomes in patients who have undergone chemotherapy or an allogeneic hematopoietic stem cell transplant for a high-grade myeloid neoplasm, acute myeloid leukemia, or B acute lymphoblastic lymphoma/leukemia. Some types of chemotherapy and stem cell transplants can induce low platelet counts and/or anemia that requires PRBC transfusions. Given critical shortages in blood supply, and risks associated with transfusion of PRBC, there has been much investigation into the "minimum" hemoglobin level that effectively balances safety and toxicity in patients. This clinical trial evaluates the effects of giving PRBC transfusions based on a more restrictive hemoglobin threshold (> 7 gm/dL) compared to a more liberal hemoglobin threshold (> 9 gm/dL) on quality of life and functional outcomes. A more restrictive threshold may be just as effective at maintaining patient quality of life and function while decreasing side effects from blood transfusions and helping to conserve blood supply resources.
The 2 groups in the trial
- Arm I (restrictive threshold)Treatment being tested
Patients undergo PRBC transfusion if at any point their hemoglobin level is 7 gm/dL or less, starting the day after SOC chemotherapy/stem cell infusion is complete and continuing for up to 42 days. Patients also undergo collection of blood samples on study.
Treatment: Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, and Quality-of-Life Assessment
- Arm II (liberal threshold)Treatment being tested
Patients undergo PRBC transfusion if at any point their hemoglobin level is 9 gm/dL or less, starting the day after SOC chemotherapy/stem cell infusion is complete and continuing for up to 42 days. Patients also undergo collection of blood samples on study.
Treatment: Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, and Quality-of-Life Assessment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Red Blood Cell Transfusion Threshold-Specific Bleeding, Quality of Life and Functional Outcomes in Acute Leukemia Patients With Thrombocytopenia: a Randomized Feasibility Study
- Plain-language title
- Tests two red blood cell transfusion levels in adults with acute leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 August 2026